SAN DIEGO, March 15, 2011 (GLOBE NEWSWIRE) -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) expects to announce its 2010 financial results for the fourth quarter and fiscal year before the market opens on Monday, March 28, 2011.
TearLab is pleased to invite all interested parties to participate in a conference call during which time financial results will be discussed. The call will be held on March 28, 2011, at 8:30a.m. Eastern Daylight Savings Time at 877-303-1593 (within the United States and Canada).
Listen via Internet: http://www.tearlab.com/us/shareholder.htm/
Schedule this webcast into MS-Outlook calendar (click open when prompted):
For those wishing to listen to a recording of the call via telephone, a replay will be made available by 11:30am EDT after the conclusion of the live call and will remain posted for a period of seven days. To listen to the recording, simply telephone (800) 642-1687 or (706) 645-9291 and enter reservation # 52311846 when prompted.
About TearLab Corporation
TearLab Corporation ( www.tearlab.com ) develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab(r) Osmolarity Test, that enables eye care practitioners to test for highly sensitive and specific biomarkers using nanoliters of tear film at the point-of-care, is the first assay developed for the award winning TearLab Osmolarity System. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.
Forward-Looking Statements
This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about TearLab. Examples of forward-looking statements in this press released include predictions regarding the sufficiency of current cash and cash equivalents to fund operations for 12 months or more, intent to submit a revised CLIA waiver application, building sales in Europe and Canada, seeking CLIA waiver and Medicare reimbursement, and the future commercial adoption of the TearLab(tm) Osmolarity System. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our annual and quarterly reports on Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.
CONTACT: Kilmer Lucas Inc. Stephen Kilmer (President) 905 690-2400 Ext.21 stephen@kilmerlucas.com Kilmer Lucas Inc. Leonard Zehr (Managing Director) 905 690 2400 Ext.41 len@kilmerlucas.com